Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:03:06 EDT Sun 31 Aug 2025
Enter Symbol
or Name
USA
CA



Q:INCY - INCYTE CORPORATION - https://www.incyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q0.177.39·85.006.084.61+0.911.11,338.3112,14111,84983.85  84.63  83.40587.24  53.5619:59:23Aug 2715 min RT 2¢

Recent Trades - Last 10 of 11849
Time ETExPriceChangeVolume
19:59:23Q85.001.3010
17:14:45Q84.620.9210
16:38:22Q84.610.9140,133
16:20:00Q84.610.91693
16:18:32Q84.610.9113
16:14:11Q83.40-0.301
16:10:21Q84.610.91188
16:10:04Q84.610.911
16:10:04Q84.610.911
16:10:04Q84.610.911

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-08-27 16:15U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-08-25 08:00U:INCYNews ReleaseIncyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
2025-08-19 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2025-08-05 16:05U:INCYNews ReleaseIncyte Announces Departure of Chief Financial Officer Christiana Stamoulis
2025-08-04 16:30U:INCYNews ReleaseKnight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
2025-07-31 16:30U:INCYNews ReleaseKnight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Brazil
2025-07-29 07:00U:INCYNews ReleaseIncyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2025-07-24 17:02U:INCYNews ReleaseIncyte To Present Initial Data for its TGFbetaR2*PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
2025-07-10 08:00U:INCYNews ReleaseIncyte to Report Second Quarter Financial Results
2025-07-02 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-06-26 07:30U:INCYNews ReleaseIncyte Appoints Bill Meury Chief Executive Officer; Herve Hoppenot to Retire
2025-06-20 16:30U:INCYNews ReleaseUpdate on FDA Review of Ruxolitinib Cream (Opzelura(TM)) for Children Ages 2-11 with Atopic Dermatitis
2025-06-18 15:39U:INCYNews ReleaseIncyte Announces FDA Approval of Monjuvi(TM) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
2025-06-15 04:00U:INCYNews ReleaseQIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
2025-06-15 03:15U:INCYNews ReleasePositive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
2025-06-12 18:45U:INCYNews ReleasePhase 3 Data for Incyte's Retifanlimab (Zynyz(TM)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
2025-06-06 16:30U:INCYNews ReleaseIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-03 10:30U:INCYNews ReleaseIncyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
2025-05-27 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2025-05-15 14:30U:INCYNews ReleaseIncyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States